Peng Ke currently serves as the Director of Dosage Form Design and Development at AstraZeneca since August 2025 and as a Visiting Lecturer at King's College London since April 2022. Previously, Peng held the position of Director of CMC at WuXi Biologics from August 2023 to July 2025, leading multidisciplinary teams in the development of biologics programs within the UK/EU region. Peng's extensive experience at AstraZeneca from February 2014 to August 2023 includes roles as Associate Director and Associate Principal Scientist, overseeing drug product and CMC teams to advance biologics through various clinical phases. Prior positions include senior scientist roles at MSD and Pharmaterials Limited, as well as a formulation scientist at Emergent BioSolutions. Educational credentials include an MBA from the University of Cambridge, a PhD in Pharmaceutics from UCL, and a BEng in Pharmaceutics from Shenyang Pharmaceutical University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices